GeneDx Holdings Corp.
WGS
$83.65
-$1.13-1.33%
| Weiss Ratings | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.40 | |||
| Price History | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.13% | |||
| 30-Day Total Return | -12.59% | |||
| 60-Day Total Return | -6.27% | |||
| 90-Day Total Return | 4.13% | |||
| Year to Date Total Return | 5.21% | |||
| 1-Year Total Return | 702.49% | |||
| 2-Year Total Return | 718.96% | |||
| 3-Year Total Return | -5.27% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -26.67% | |||
| 52-Week Low % Change | 881.95% | |||
| Price | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $115.60 | |||
| 52-Week Low Price | $8.63 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Feb 19, 2025 | |||
| Valuation | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.38B | |||
| Enterprise Value | 2.35B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.98 | |||
| Earnings Per Share Growth | -73.59% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.71 | |||
| Price/Book (Q) | 9.68 | |||
| Enterprise Value/Revenue (TTM) | 7.71 | |||
| Price | $83.78 | |||
| Enterprise Value/EBITDA (TTM) | -5,770.42 | |||
| Enterprise Value/EBIT | -109.70 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 27.78M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 888 729 1206 | |||
| Address | North Tower Stamford, CT 06902 | |||
| Website | www.genedx.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -7.02% | |||
| Profit Margin | -17.11% | |||
| Management Effectiveness | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.20% | |||
| Return on Equity | -- | |||
| Income Statement | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 302.16M | |||
| Total Revenue (TTM) | 305.45M | |||
| Revenue Per Share | $10.99 | |||
| Gross Profit (TTM) | 194.45M | |||
| EBITDA (TTM) | -408.00K | |||
| EBIT (TTM) | -21.46M | |||
| Net Income (TTM) | -52.29M | |||
| Net Income Avl. to Common (TTM) | -52.29M | |||
| Total Revenue Growth (Q YOY) | 66.57% | |||
| Earnings Growth (Q YOY) | 121.10% | |||
| EPS Diluted (TTM) | -1.98 | |||
| EPS Diluted Growth (Q YOY) | 119.68% | |||
| Balance Sheet | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 141.19M | |||
| Cash Per Share (Q) | $5.08 | |||
| Total Current Assets (Q) | 197.97M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 245.25M | |||
| Current Ratio (Q) | 3.611 | |||
| Book Value Per Share (Q) | $8.75 | |||
| Total Assets (Q) | 419.38M | |||
| Total Current Liabilities (Q) | 54.82M | |||
| Total Debt (Q) | 116.17M | |||
| Total Liabilities (Q) | 174.13M | |||
| Total Common Equity (Q) | 245.25M | |||
| Cash Flow | WGS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -30.13M | |||
| Cash from Financing (TTM) | 44.16M | |||
| Net Change in Cash (TTM) | -14.47M | |||
| Levered Free Cash Flow (TTM) | 1.61M | |||
| Cash from Operations (TTM) | -28.50M | |||
